Thinking About GLP-1 Medications? Here’s What to Eat (and What Most People Get Wrong)

If you’ve been hearing more about medications like Ozempic, Wegovy, or Mounjaro, you’re not alone.

Many of the people I work with are either considering a GLP-1 medication, already taking one, or trying to figure out how to make it work long-term.

These medications can be incredibly helpful. But there’s one piece that often gets overlooked:

What you do alongside the medication matters just as much as the medication itself.

Without the right nutrition and habits, people can lose muscle, feel fatigued, or struggle to maintain results over time.

How GLP-1 Medications Work (In Real Life)

GLP-1 medications mimic a hormone your body naturally releases after eating. That hormone helps regulate blood sugar, reduce appetite, and slow digestion.

Most people notice that they feel full sooner, think about food less, and don’t have the same pull toward snacking or overeating. That’s a big part of why these medications can be so effective.

But eating less is not the same as being well-nourished—and that’s where I see people run into trouble.

What Most People Get Wrong

One of the most common patterns I see is that people eat significantly less, but don’t change what they’re eating.  The habits of what you eat need to evolve a bit, too.

Over time, that can lead to low energy, muscle loss, and nutrient gaps that make it harder to feel well—or to sustain the results they’re seeing.

The goal isn’t just weight loss.

It’s losing fat while maintaining muscle and supporting your long-term health.

What to Focus on Instead

When appetite drops, every bite matters more.

That’s why I usually start with protein. Most people need more than they think, especially when they’re losing weight. Protein helps maintain muscle, supports metabolism, and keeps energy more stable throughout the day. This can look like adding eggs or Greek yogurt in the morning, incorporating chicken, fish, or beans into meals, and making sure snacks include something more substantial than just carbohydrates.

Fiber is another key piece. It supports digestion, helps regulate blood sugar, and can make a big difference in how you feel day to day—especially since constipation is a common side effect of these medications. Simple additions like vegetables, lentils, oats, and whole grains can go a long way.

Because appetite is lower, large meals don’t always feel good. Many people do better with smaller, more frequent meals, focusing on nutrient-dense foods rather than trying to force large portions.

Hydration also becomes more important than people expect. These medications slow digestion, and without enough fluid, symptoms like nausea or constipation can worsen. Drinking water or unsweetened beverages consistently throughout the day can make a noticeable difference.

Protecting Muscle While You Lose Weight

This is one of the most important pieces—and one that’s often overlooked.

When weight loss happens quickly, the body doesn’t just lose fat. Without enough protein and resistance exercise, muscle loss can happen too.

Over time, that can affect metabolism, strength, and how sustainable the results are.

The goal is to support your body while it’s changing, not just reduce the number on the scale. That usually means being intentional about protein intake and incorporating some form of resistance training a few times per week, even if it’s simple and done at home.

What About Side Effects?

Some people experience nausea, constipation, or occasional digestive changes—especially in the beginning or when doses increase.

Most of the time, these can be improved with small adjustments. Eating a bit more slowly, choosing simpler foods when appetite is low, staying hydrated, and making sure fiber intake is appropriate can all help.

These symptoms are common, and for many people, they settle as the body adjusts.

The Bigger Picture

GLP-1 medications can be a powerful tool, but they don’t replace habits.

The people who tend to do best long-term are the ones who use this time to build a different relationship with food—one that’s more structured, more intentional, and more aligned with how their body actually works.

This is often where the real transformation happens.

When It Makes Sense to Get Support

If you’re taking (or considering) a GLP-1 medication and feeling unsure about what to eat, how much to eat, or how to make results sustainable, you’re not alone.

This is where working with a dietitian can be especially helpful—because we can look at your labs, your lifestyle, and your goals together and create something that actually fits your life.

Final Thought

GLP-1 medications can help initiate change.

But what you do alongside them is what determines whether that change lasts.

Ready for Support?

If you want a clear, realistic plan to support your nutrition while using a GLP-1 medication: working with a dietitian experienced in metabolic health can be a game-changer.

👉 Nutrition counseling is often covered by insurance.

You can learn more at www.nutritiondecode.com or

schedule your first appointment here

References

• Aronne, L.J., Sattar, N., & Horn, D.B. (2024). Continued treatment with Tirzepatide for maintenance of weight reduction in adults with obesity. JAMA, 331(1), 38-48. https://doi.org/10.1001/jama.2023.24945.

• Blum, D. (2023, June 21). People on drugs like Ozempic say their “food noise” has disappeared. The New York Times. Retrieved November 13, 2024, from https://www.nytimes.com/2023/06/21/well/eat/ozempic-food-noise.html

• Bodnaruc, A.M., Prud’homme, D., Blanchet, R., & Giroux, I. (2016). Nutritional modulation of endogenous glucagon-like peptide-1 secretion: A review. Nutrition & Metabolism, 13, 92. https://doi.org/10.1186/s12986-016-0153-3.

• Campos-Nonato, I., Hernandez, L., & Barquera, S. (2017). Effect of a high-protein diet versus standard-protein diet on weight loss and biomarkers of metabolic syndrome: a randomized clinical trial. Obesity Facts, 10(3), 238-251. https://doi.org/10.1159/000471485.

• Carbone, J.W., & Pasiakos, S.M. (2019). Dietary protein and muscle mass: Translating science to application and health benefits. Nutrients, 11(5), 1136. https://doi.org/10.3390/nu11051136.

• Garvey, W.T., Batterham, R.L., Bhatta, M., Buscemi, S., Christensen, L.N., Frias, J.P., Jódar, E., Kandler, K., Rigas, G., Whadden, T.A., Wharton, S, & STEP 5 Investigators. (2022). Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial. Nature Medicine, 28(10), 2083-2091. https://doi.org/10.1038/s41591-022-02026-4.

• Huber, H., Schieren, A., Holst, J.J., & Simon, M.C. (2024). Dietary impact on fasting and stimulated GLP-1 secretion in different metabolic conditions - A narrative review. The American Journal of Clinical Nutrition, 119(3), 599–627. https://doi.org/10.1016/j.ajcnut.2024.01.007.

• Jastreboff, A.M., Aronne, L.J., Ahmad, N.N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M.C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine, 387(3), 205-216. https://doi.org/10.1056/NEJMoa2206038.

• Kobylińska, M., Antosik, K., Decyk, A., & Kurowska, K. (2022). Malnutrition in obesity: is it possible? Obesity Facts, 15(1), 19–25. https://doi.org/10.1159/000519503.

• Mahapatra, M.K., Karuppasamy, M., & Sahoo, B.M. (2022). Semaglutide, a glucagon-like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Reviews in Endocrine and Metabolic Disorders, 23(3), 521-539. https://doi.org/10.1007/s11154-021-09699-1.

• McCarthy, D., & Berg, A. (2021). Weight loss strategies and the risk of skeletal muscle mass loss. Nutrients, 13(7), 2473. https://doi.org/10.3390/nu13072473.

• National Institutes of Health. (2024, July 24). Calcium fact sheet for health professionals. Retrieved November 13, 2024, from https://ods.od.nih.gov/factsheets/Calcium-HealthProfessional/

• National Institutes of Health. (2024, October 9). Iron fact sheet for health professionals. Retrieved November 13, 2024, from https://ods.od.nih.gov/factsheets/Iron-HealthProfessional/

• National Institutes of Health. (2024, July 26). Vitamin D fact sheet for health professionals. Retrieved November 13, 2024, from https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/

• Nauck, M.A., Quast, D.R., Wefers, J., & Pfeiffer, A.F.H. (2021). The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update. Diabetes, Obesity and Metabolism, 23(3), 5-29. https://doi.org/10.1111/dom.14496.

• NovoMEDLINK. (n.d.). Important safety information for Wegovy®. Retrieved November 13, 2024, from https://www.novomedlink.com/obesity/products/treatments/wegovy.html#Wegovy-HCP-isi

• Patoulias, D., Papadopoulos, C., & Doumas, M. (2022). Tirzepatide versus semaglutide once weekly in type 2 diabetes. The New England Journal of Medicine, 386(7), e17. https://doi.org/10.1056/nejmc2114590.

• Rubino, D., Abrahamsson, N., & Davies, M. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity. JAMA, 25(14), 1414-1425. https://doi.org/10.1001/jama.2021.3224

• U.S. Food & Drug Administration. (2024, October 02). FDA’s concerns with unapproved glp-1 drugs used for weight loss. Retrieved November 13, 2024, from https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

• Wadden, T.A., Bailey, T.S., Billings, L.K., Davies, M., Frias, J.P., Koroleva, A., Lingvay, I., O'Neil, P.M., Rubino, D.M., Skovgaard, D., Wallenstein, S.O.R., Garvey, W.T., & STEP 3 Investigators. (2021). Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: The STEP 3 randomized clinical trial. JAMA, 325(14), 1403-1413. https://doi.org/10.1001/jama.2021.1831

• Wharton, S., Davies, M., Dicker, D., Lingvay, I., Mosenzon, O., Rubino, D.M., & Pederson, S.D. (2022). Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: Recommendations for clinical practice. Postgraduate Medicine, 134(1), 14-19. https://doi.org/10.1080/00325481.2021.2002616

• Wilding, J.P.H., Batterham, R.L., Calanna, S., Davies, M., Van Gaal, L.F., Lingvay, I., McGowan, B.M., Rosenstock, J., Tran, M.T.D., Wadden, T.A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R.F. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989-1002. https://doi.org/10.1056/NEJMoa2032183.